Clinical Biomarkers awards

We have launched a new funding scheme to identify and implement molecular testing for those affected by a brain tumour.

As part of 'A Cure Can't Wait' we are launching a new scheme to ensure that each patient benefits from an early and accurate diagnosis.

Purpose and scope

This scheme supports the identification of markers, validation of markers and their implementation into routine clinical use in the UK. Studies may make use of the samples and infrastructure brought about by funded clinical trials, to go beyond the primary and secondary endpoints and generate new knowledge around clinical biomarkers.


Guide costs: up to £100,000 per year for up to five years

This funding should be primarily allocated to cover direct costs of consumables, and additional FTE costs where appropriate justification is made. Requests for capital /infrastructure will not be considered since it is expected that this will be available at the Lead Institution as well as all partner organisations.

Grants will be awarded to the Principal Applicant's institution. Funding can be allocated to co-investigator institutions with agreements put in place between all partner institutions.

Application process

Applications will open in early 2017 and there is no deadline for this call. Proposals will be accepted on a rolling basis.

Applications must be submitted online through our new portal: proposalCENTRAL. Please do take the time to get familiar with the site, set up an account and start filling in your profile.

The Brain Tumour Charity is a member of the Association of Medical Research Charities (AMRC) and adheres to its principles of peer review. Applications will be awarded through a competitive peer reviewed process (in line with AMRC principles) and then considered by our Scientific Advisory Boards (SABs).

Eligibility criteria

  • All grant applications must address the issue of earlier and accurate diagnosis, as highlighted in our Research Strategy 'A Cure Can't Wait'.
  • This award is open to international researchers, but all proposals must demonstrate how they can benefit patients in the UK health system.
  • Applications MUST include a clinical AND a scientific lead.
  • It will be looked on favourable if this proposal makes use of the infrastructure and/or samples already in use for a funded trial.
  • If proposals are submitted in the context of an already funded clinical trial then this funding should be from an agency which uses peer reviewing methods in its grant assessment (e.g. Cancer Research UK).
  • Similarly, if proposals are submitted in the context of an already funded clinical trial, the funding obtained may not be used for the purposes of achieving the primary or second endpoints of the trial as this should be covered by the initial funding. Funding is intended to allow the production of new insights (e.g. identification of new biomarkers or further stratification of the trial population) which will lead us to early and accurate diagnosis.

Assessment criteria

Projects must have a sound approach and methodology in order to address the questions raised

Statistical validity
Projects must be statistically powered so results are significant and meaningful.

Expertise of Applicants
The applicants must be appropriately trained and well suited to carry out the planned studies.

Potential for patient benefit
Projects must articulate a clear pathway leading to patient benefit as well as the anticipated impact and likelihood of achieving an early and accurate diagnosis. Applications with a clear path to clinical or practical application will be strongly favoured. In addition, applications need to demonstrate how their findings will be taken up and funded by the NHS following The Charity's investment.

Value for money
Projects must demonstrate that the funds requested are essential for the work and how these represent value for money.

Key dates

The call will be open for applications throughout the year and decisions will be made at existing SAB meetings. At the time of proposal, applicants will be told when their SAB assessment will take place.

Further information

Guidance notes for this award will be made available soon.

All applications need to have Patient or Public Involvement (PPI) at any stage of their proposal. To facilitate this, you may choose to engage with The Charity's Research Involvement Network (RIN). This is a virtual network of people who either have a brain tumour themselves, or care for someone who does. For them, participation in your project at any stage of its development and in any capacity, would mean using their own personal experience of this devastating disease for the greater good.

If you have any queries or would like to discuss your application, please do get in touch with us:


Phone: +44 (0) 1252 418190